Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide.
about
The Rationale for Insulin Therapy in Alzheimer's DiseaseMetformin and thyroid: an updateMetformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathyRole of anti-diabetic drugs as therapeutic agents in Alzheimer's diseaseMetformin Prevents Cisplatin-Induced Cognitive Impairment and Brain Damage in MiceMetformin Prevents Nigrostriatal Dopamine Degeneration Independent of AMPK Activation in Dopamine NeuronsAntioxidant and Anti-Senescence Effect of Metformin on Mouse Olfactory Ensheathing Cells (mOECs) May Be Associated with Increased Brain-Derived Neurotrophic Factor Levels-An Ex Vivo Study.Berberine Ameliorates Diabetes-Associated Cognitive Decline through Modulation of Aberrant Inflammation Response and Insulin Signaling Pathway in DM Rats.Chronic metformin treatment improves post-stroke angiogenesis and recovery after experimental stroke.To Use or Not to Use Metformin in Cerebral Ischemia: A Review of the Application of Metformin in Stroke RodentsRepurposing diabetes drugs for brain insulin resistance in Alzheimer disease.Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives.Offsetting the impact of smoking and e-cigarette vaping on the cerebrovascular system and stroke injury: Is Metformin a viable countermeasure?Metformin: good or bad for the brain?Metformin exaggerates phenylephrine-induced AMPK phosphorylation independent of CaMKKβ and attenuates contractile response in endothelium-denuded rat aorta.Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion currentAntihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathwayThe effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.Metformin inhibits growth of human glioblastoma cells and enhances therapeutic responseDemonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.Clinical Characteristics for the Relationship between Type-2 Diabetes Mellitus and Cognitive Impairment: A Cross-Sectional StudyMammalian target of rapamycin is required for phrenic long-term facilitation following severe but not moderate acute intermittent hypoxia.Metformin Does Not Suppress Serum Thyrotropin by Increasing Levothyroxine AbsorptionBeneficial Effects of Metformin and/or Salicylate on Palmitate- or TNFα-Induced Neuroinflammatory Marker and Neuropeptide Gene Regulation in Immortalized NPY/AgRP NeuronsEffects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study.Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J miceGlioma-initiating cell elimination by metformin activation of FOXO3 via AMPK.Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2.Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies.The impact of the metabolic phenotype on thyroid function in obesity.Retinal proteome alterations in a mouse model of type 2 diabetes.Deciphering Brain Insulin Receptor and Insulin-Like Growth Factor 1 Receptor Signalling.Metformin Impairs Spatial Memory and Visual Acuity in Old Male Mice.Rescue of mutant rhodopsin traffic by metformin-induced AMPK activation accelerates photoreceptor degeneration.The interface between thyroid and diabetes mellitus.New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells.Glioma stem cells: markers, hallmarks and therapeutic targeting by metformin.Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumoursAre microRNAs the Molecular Link Between Metabolic Syndrome and Alzheimer's Disease?Impaired insulin action in the human brain: causes and metabolic consequences.
P2860
Q26744834-74B7A277-D811-4ABE-9AC9-56C633EA8040Q26822045-AC8DA683-2CE5-4D4E-A5EF-B1728AF9C9B0Q27301246-5BBC21E6-F039-4410-8C6D-B8219E2AEFF1Q28083039-A5EDA962-D631-4CFA-BD3E-EC2C65C59E8BQ28551025-E9D2E040-DF36-4B41-9A07-316EC65BE2E9Q28553200-9A414593-6A9D-4E25-934D-3ED2471C12BDQ33624944-445D8F07-4C43-42BF-9A40-718B7E275F72Q33766908-B417C33D-2C90-415A-8A69-DDCDC6D07464Q33769776-824F6827-5E02-4ED8-A07C-BC212560F6CEQ33787067-9DECF820-27A6-4795-8380-8DC96B5BD2FDQ33789329-DDC491DB-B900-40CC-B69A-02E97905302DQ33800802-7558B041-83B6-491B-AE32-3BD645A38018Q33825485-F52CA27A-4CE8-4DE5-88DE-65C35DFC54DEQ34357962-56C7D02E-9973-422D-9DAD-64D1754C11E6Q34616393-EB612AF6-06FF-432E-8A39-7B136975A100Q34957274-9488DAFD-1EB3-4351-BEEE-F526E1E77E02Q35029506-8078FE19-E0B2-4ED6-97FA-526D13EF65DCQ35546563-9D74B338-CE37-431F-B8DE-5512822A3E75Q35600122-4098FF23-8B7F-4188-A8C9-8B332A5BB6B6Q35858095-AB44B409-6E4D-4893-9DB4-3434FAAA428AQ35871576-751E25AE-4690-45B8-9DDD-7C4355F588F8Q36064784-77E1C917-52CA-4CF6-80A0-9C3FC73B82E8Q36108068-310D8217-E89A-4381-BB82-94A54521E3C0Q36205527-3774B585-F775-46EF-8816-85CE7F6564AEQ36379186-61FB867C-9128-4425-9A3D-850BA85830FEQ36771663-DCBB1F8D-8C97-4B9D-81D1-971D21001038Q36861418-2A5ACBBF-D2D5-453B-AC22-70634672C3C7Q37118676-304A7902-DC6A-4247-99E1-6DD243455BF8Q37158071-CDB7AF82-8840-4A15-9149-7C6F0C7BA35CQ37199254-740E0E3B-3581-471B-8D1D-AC2049753A3AQ37374086-C3C4E63F-19F2-4770-A6C8-23190594E704Q37456221-F7E89A32-C1CF-4754-A770-404ED302E8D4Q37619208-D055E7A9-5A48-4B81-974F-E55358D2F588Q37701985-88897D3D-61C9-44BE-BB1E-F99434E29AA4Q37869199-743DFE17-8246-401C-A5CE-B2BCE2E4B295Q38187997-F16B087A-661A-455F-88C0-FD76E5DB3690Q38244345-7BF76F41-6B0D-4939-9BCA-54AD05647A59Q38375735-6266F9A7-AA74-4915-912B-85F788106E77Q38481462-5AD56D88-5D24-46E9-B5C4-FCD312650CB8Q38605675-43197CB5-011E-48E8-87BB-153F879DAABF
P2860
Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Quantification of metformin by ...... eated with lipopolysaccharide.
@en
Quantification of metformin by ...... eated with lipopolysaccharide.
@nl
type
label
Quantification of metformin by ...... eated with lipopolysaccharide.
@en
Quantification of metformin by ...... eated with lipopolysaccharide.
@nl
prefLabel
Quantification of metformin by ...... eated with lipopolysaccharide.
@en
Quantification of metformin by ...... eated with lipopolysaccharide.
@nl
P2093
P921
P1476
Quantification of metformin by ...... reated with lipopolysaccharide
@en
P2093
Anna Bielecka
Bożena Gabryel
Dariusz Suchy
Krzysztof Łabuzek
Sebastian Liber
P304
P356
10.1016/S1734-1140(10)70357-1
P577
2010-09-01T00:00:00Z